Slide this table
|Purity Confirmation||> 95% by SDS-PAGE|
|Molecular Weight||6.35 kDa|
|N Terminal Sequence||MNSDSECPLS|
|Biological Activity||The biological activity was determined by the ability to induce EGF receptor phosphorylation in the A431 tumor cell line [Soler et al, J Chromatography B, 788, 2003] and the induction of proliferation in NHDF cells (Normal Human Dermal Fibroblasts).|
|Species Reactivity||human, mouse|
|Reconstitution||We recommend a quick spin followed by reconstitution in water to a concentration of 0.1-1.0 mg/ml.|
|Stability and Storage||The lyophilized protein is stable for a few weeks at room temperature, but best stored at -20°C. Reconstituted EGF should be stored in working aliquots at -20°C.|
|Synonyms||Epidermal growth factor; EGF; URG; HOMG4; Urogastrone|
|Description||Epidermal growth factor (EGF) is the founding member of the EGF family that also includes TGFα, amphiregulin (AR), betacellulin (BTC), epiregulin (EPR), heparin-binding EGF-like growth factor (HBEGF), epigen, and the neuregulins (NRG) 1 through 6. Members of the EGF family share a structural motif, the EGF-like domain, which is characterized by three intra-molecular disulfide bonds that are formed by six similarly spaced conserved cysteine residues. All EGF family members are synthesized as type I transmembrane precursor proteins that may contain several EGF domains in the extracellular region. The mature proteins are released from the cell surface by regulated proteolysis. The 1207 amino acid (aa) human EGF precursor contains nine EGF domains and nine LDLR class B repeats. The mature protein consists of 53 aa and is generated by proteolytic excision of the EGF domain proximal to the transmembrane region. Mature human EGF shares 70% aa sequence identity with mature mouse and rat EGF. EGF is present in various body fluids, including blood, milk, urine, saliva, seminal fluid, pancreatic juice, cerebrospinal fluid, and amniotic fluid. Four ErbB (HER) family receptor tyrosine kinases including EGFR/ErbB1, ErbB2, ErbB3 and ErbB4, mediate responses to EGF family members. EGF binds ErbB1 and depending on the context, induces the formation of homodimers or heterodimers containing ErbB2. Biological activities ascribed to EGF include epithelial development, angiogenesis, inhibition of gastric acid secretion, fibroblast proliferation, and colony formation of epidermal cells in culture.|
- Scaffold-Based (Matrigel™) 3D Culture Technique of Glioblastoma Recovers a Patient-like Immunosuppressive Phenotype. F. K. Braun et al., Cells. 2023 Jul; 12(14): 1856.
- AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma. M.I. Strecker et al., Oncoimmunology. 2022; 11(1): 2127508.
- 3D-printed scaffold composites for the stimuli-induced local delivery of bioactive adjuncts. A. Bandiera et al., Biotechnology and Applied Biochemistry
- Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide. N. I. Lorenz et al., Sci Rep. 2021; 11: 14161.
- FGF2 Inhibits Early Pancreatic Lineage Specification during Differentiation of Human Embryonic Stem Cells. R. Dettmer et al., Cells. 2020 Sep; 9(9): 1927.
- Disruption of peroxisome proliferator–activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells. I. Bruns et al., J Biol Chem. 2019 Mar 1; 294(9): 3037–3050.
- Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions. Schulze M. et al., BMC Cancer. 2018 May 3;18(1):524.
- Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. G. Kohanbash et al., J Clin Invest. 2017 Apr 3; 127(4): 1425–1437.
- Inhibition of cell cycle progression by the hydroxytyrosol–cetuximab combination yields enhanced chemotherapeutic efficacy in colon cancer cells. E. Terzuoli et al., Oncotarget. 2017 Oct 10; 8(47): 83207–83224.
- Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas. L. Jennewein et al., Oncotarget. 2016 Apr 12; 7(15): 20016–20032.
- Molecular dissection of the valproic acid effects on glioma cells. S. Hoja et al., Oncotarget. 2016 Sep 27; 7(39): 62989–63002.
- Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5. A. Fassl et al., Cell Death Dis. 2015 Oct; 6(10): e1921.
- Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. S. Genßler et al., Oncoimmunology. 2016 Apr; 5(4): e1119354.
- Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors. P. N. Harter et al., PLoS One. 2015; 10(5): e0127123.
- Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid. S. Fischer et al., PLoS One. 2014; 9(4): e94921.
- EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity. Donnini S et al., Oncogene. 2012 Jul 19;31(29):3457-66.
- The role of recombinant epidermal growth factor and serotonin in the stimulation of tumor growth in a SCCHN xenograft model. C. Geissler et al., Oncol Rep. 2012 Sep; 28(3): 785–790.
- Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. F. Zanella et al., BMC Cell Biol. 2009; 10: 14.
All prices plus VAT + possible delivery charges